Psychosis and Suicide

  • Tatiana FalconeEmail author
  • Migle Staniskyte
  • Jane Timmons-Mitchell


Among the 21 million people in the world with schizophrenia, the risk of suicide is high. Some studies indicate that about ¼ of schizophrenics will attempt suicide, while others place the estimate higher. There is agreement that the time between diagnosis and engagement with evidence-based treatment for first-episode psychosis is a time of high risk for suicide. Early identification and intervention can be helpful, and protective factors can be strengthened. The chapter discusses screening and assessment instruments specific to psychosis and suicide. Connecting with treatment providers early after the discovery of psychosis is key, as is working with a psychiatrist to find the most helpful medication regimen. Evidence-based treatments are reviewed. It is recommended that patients with psychosis should be carefully monitored for suicide risk.


Schizophrenia Psychosis Suicide First-episode psychosis Evidence-based treatment Early intervention Cognitive behavioral therapy Multisystemic therapy 


  1. 1.
    World Health Organization. Schizophrenia: fact sheet. 2016.
  2. 2.
    National Institute of Mental Health. Schizophrenia. 2017.
  3. 3.
    McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76.CrossRefPubMedGoogle Scholar
  4. 4.
    Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cardno AG, Gottesman II. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet. 2000;97(1):12–7.CrossRefPubMedGoogle Scholar
  6. 6.
    McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2(1):13.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Zhang XY, Chen DC, Xiu MH, Yang FD, Haile CN, Kosten TA, et al. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry. 2012;73(7):1025–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Mathers CD, Stein C, Ma Fat D, Rao C, Inoue M, Tomijima N, et al. Global Burden of Disease 2000: version 2 methods and results. Geneva: World Health Organization; 2002. Google Scholar
  9. 9.
    Wijngaarden van B, Schene AH, Koeter M, Vazquez-Barquero JL, Knudsen HC, Lasalvia A, et al. Caregiving in schizophrenia: development, internal consistency and reliability of the Involvement Evaluation Questionnaire-European Version. Br J Psychiatry. 2000;77(39):s21–7.CrossRefGoogle Scholar
  10. 10.
    Nordentoft M, Laursen TM, Agerbo E, Qin P, Høyer EH, Mortensen PB. Change in suicide rates for patients with schizophrenia in Denmark, 1981–97: nested case-control study. BMJ. 2004;329(7460):261.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247–53.CrossRefPubMedGoogle Scholar
  12. 12.
    Andreasen NC, Black DW, editors. Introductory textbook of psychiatry. 4th ed. Arlington: American Psychiatric Publishing; 2006.Google Scholar
  13. 13.
    Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15(2):127–35.CrossRefPubMedGoogle Scholar
  14. 14.
    Pompili M, Mancinelli I, Tatarelli R. Suicide and schizophrenia. Psych Serv. 2003;54(5):747–8.CrossRefGoogle Scholar
  15. 15.
    Joa I, Johannessen JO, Langeveld J, Friis S, Melle I, Opjordsmoen S, et al. Baseline profiles of adolescent vs. adult-onset first-episode psychosis in an early detection program. Acta Psychiatr Scand. 2009;119(6):494–500.CrossRefPubMedGoogle Scholar
  16. 16.
    Munk-Jørgensen P, Mortensen PB. Social outcome in schizophrenia: a 13-year follow-up. Soc Psychiatry Psychiatr Epidemiol. 1992;27(3):129–34.PubMedGoogle Scholar
  17. 17.
    Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry. 1997;171(6):502–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Haw C, Hawton K, Sutton L, Sinclair J, Deeks J. Schizophrenia and deliberate self-harm: a systematic review of risk factors. Suicide Life Threat Behav. 2005;35(1):50–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Montross LP, Zisook S, Kasckow J. Suicide among patients with schizophrenia: a consideration of risk and protective factors. Ann Clin Psychiatry. 2005;17(3):173–82.CrossRefPubMedGoogle Scholar
  20. 20.
    Barrett EA, Sundet K, Faerden A, Nesvåg R, Agartz I, Fosse R, et al. Suicidality before and in the early phases of first episode psychosis. Schizophr Res. 2010;119(1):11–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Melle I, Ann Barrett E. Insight and suicidal behavior in first-episode schizophrenia. Expert Rev Neurother. 2012;12(3):353–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Falcone T, Mishra L, Carlton E, Lee C, Butler R, Janigro D, et al. Suicidal behavior in adolescents with first-episode psychosis. Clin Schizophr Relat Psychoses. 2010;4(1):34–40.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kelleher I, Corcoran P, Keeley H, Wigman JT, Devlin N, Ramsay H, et al. Psychotic symptoms and population risk for suicide attempt: a prospective cohort study. JAMA Psychiat. 2013;70(9):940–8.CrossRefGoogle Scholar
  24. 24.
    Madsen T, Karstoft KI, Secher RG, Austin SF, Nordentoft M. Trajectories of suicidal ideation in patients with first-episode psychosis: secondary analysis of data from the OPUS trial. Lancet Psychiatry. 2016;3(5):443–50.CrossRefPubMedGoogle Scholar
  25. 25.
    US Public Health Service. The Surgeon General’s call to action to prevent suicide. Washington, DC: US Department of Health and Human Services; 1999. Google Scholar
  26. 26.
    Harkavy-Friedman J. Suicide risk among people with psychosis: focus on first episode. SAMHSA sponsored webinar; June 28, 2016.
  27. 27.
    Bilsker D, White J. The silent epidemic of male suicide. B C Med J. 2011;53(10):529–34.Google Scholar
  28. 28.
    Grover S, Davuluri T, Chakrabarti S. Religion, spirituality, and schizophrenia: a review. Indian J Psychol Med. 2014;36(2):119–24.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Culliford L. Spirituality and clinical care: spiritual values and skills are increasingly recognised as necessary aspects of clinical care. BMJ. 2002;325(7378):1434–6.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Shah R, Kulhara P, Grover S, Kumar S, Malhotra R, Tyagi S. Contribution of spirituality to quality of life in patients with residual schizophrenia. Psychiatry Res. 2011;190(2):200–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Cowen EL, Wyman PA, Work WC. Resilience in highly stressed urban children: concepts and findings. Bull N Y Acad Med. 1996;73(2):267–84.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Kraus N, Chandrasekaran B. Music training for the development of auditory skills. Nat Rev Neurosci. 2010;11(8):599–605.CrossRefPubMedGoogle Scholar
  33. 33.
    Simon TR, Swann AC, Powell KE, Potter LB, Kresnow MJ, O’Carroll PW. Characteristics of impulsive suicide attempts and attempters. Suicide Life Threat Behav. 2001;32:49–59.CrossRefPubMedGoogle Scholar
  34. 34.
    Nock MK, Borges G, Bromet EJ, Cha CB, Kessler RC, Lee S. Suicide and suicidal behavior. Epidemiol Rev. 2008;30(1):133–54.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Fleegler EW, Lee LK, Monuteaux MC, Hemenway D, Mannix R. Firearm legislation and firearm-related fatalities in the United States. JAMA Intern Med. 2013;173(9):732–40.CrossRefPubMedGoogle Scholar
  36. 36.
    Barrett T. House rolls back Obama gun background check rule. CNN Politics. 3 Feb 2017.
  37. 37.
    Sundararaman R, Panangala SV, Lister SA. Suicide prevention among veterans: congressional research service report to Congress. Congressional Research Service: Washington, DC; 2008.Google Scholar
  38. 38.
    Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA, Barrios FX. The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples. Assessment. 2001;8(4):443–54.CrossRefPubMedGoogle Scholar
  39. 39.
    Preston E, Hansen L. A systematic review of suicide rating scales in schizophrenia. Crisis. 2005;26(4):170–80.CrossRefPubMedGoogle Scholar
  40. 40.
    Taiminen T, Huttunen J, Heilä H, Henriksson M, Isometsä E, Kähkönen J, et al. The Schizophrenia Suicide Risk Scale (SSRS): development and initial validation. Schizophr Res. 2001;47(2):199–213.CrossRefPubMedGoogle Scholar
  41. 41.
    Kasckow J, Felmet K, Zisook S. Managing suicide risk in patients with schizophrenia. CNS Drugs. 2011;25(2):129–43.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Zisook S, Kasckow JW, Lanouette NM, Golshan S, Fellows I, Vahia I, et al. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. J Clin Psychiatry. 2010;71(7):915–22.CrossRefPubMedGoogle Scholar
  43. 43.
    Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry. 2009;70(4):562–71.CrossRefPubMedGoogle Scholar
  44. 44.
    Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–77.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Niendam T. Integrating the C-SSRS into FEP clinical practice. SAMHSA sponsored webinar; June 28, 2016.
  46. 46.
    Lindenmayer JP, Czobor P, Alphs L, Nathan AM, Anand R, Islam Z, et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res. 2003;63(1):161–70.CrossRefPubMedGoogle Scholar
  47. 47.
    Beck AT, Steer RA, Ranieri WF. Scale for suicide ideation: psychometric properties of a self-report version. J Clin Psychol. 1988;44(4):499–505.CrossRefPubMedGoogle Scholar
  48. 48.
    Pinninti N, Steer RA, Rissmiller DJ, Nelson S, Beck AT. Use of the Beck Scale for suicide ideation with psychiatric inpatients diagnosed with schizophrenia, schizoaffective, or bipolar disorders. Behav Res Ther. 2002;40(9):1071–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Ayer DW, Jayathilake K, Meltzer HY. The InterSePT suicide scale for prediction of imminent suicidal behaviors. Psychiatry Res. 2008;161(1):87–96.CrossRefPubMedGoogle Scholar
  51. 51.
    Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187(1):9–20.CrossRefPubMedGoogle Scholar
  52. 52.
    Hunt IM, Kapur N, Robinson J, Shaw J, Flynn S, Bailey H, et al. Suicide within 12 months of mental health service contact in different age and diagnostic groups. Br J Psychiatry. 2006;188(2):135–42.CrossRefPubMedGoogle Scholar
  53. 53.
    Melle I, Johannesen JO, Friis S, Haahr U, Joa I, Larsen TK, et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry. 2006;163(5):800–4.CrossRefPubMedGoogle Scholar
  54. 54.
    Kreyenbuhl JA, Medoff DR, McEvoy JP, Smith TE, Hackman AL, Nossel IR, et al. The RAISE connection program: psychopharmacological treatment of people with a first episode of schizophrenia. Psychiatr Serv. 2016;67(12):1300–6.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Beck AT. Cognitive therapy: nature and relation to behavior therapy. Behav Ther. 1970;1(2):184–200.CrossRefGoogle Scholar
  56. 56.
    Bateman K, Hansen L, Turkington D, Kingdon D. Cognitive behavioral therapy reduces suicidal ideation in schizophrenia: results from a randomized controlled trial. Suicide Life Threat Behav. 2007;37(3):284–90.CrossRefPubMedGoogle Scholar
  57. 57.
    Zimmermann G, Favrod J, Trieu VH, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophr Res. 2005;77(1):1–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Startup M, Jackson MC, Bendix S. North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months. Psychol Med. 2004;34(03):413–22.CrossRefPubMedGoogle Scholar
  59. 59.
    Tarrier N, Kelly J, Maqsood S, Snelson N, Maxwell J, Law H, et al. The cognitive behavioural prevention of suicide in psychosis: a clinical trial. Schizophr Res. 2014;156(2):204–10.CrossRefPubMedGoogle Scholar
  60. 60.
    Tarrier N, Lewis S, Haddock G, Bentall R, Drake R, Kinderman P, et al. Cognitive-behavioural therapy in first-episode and early schizophrenia. Br J Psychiatry. 2004;184(3):231–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Henggeler SW, Schoenwald SK, Borduin CM, Rowland MD, Cunningham PB. Multisystemic treatment of antisocial behavior in children and adolescents. New York: Guilford; 1998.Google Scholar
  62. 62.
    Henggeler SW, Rowland MD, Randall J, Ward DM, Pickrel SG, Cunningham PB, et al. Home-based multisystemic therapy as an alternative to the hospitalization of youths in psychiatric crisis: clinical outcomes. J Am Acad Child Adolesc Psychiatry. 1999;38(11):1331–9.CrossRefPubMedGoogle Scholar
  63. 63.
    Huey SJ, Henggeler SW, Rowland MD, Halliday-Boykins CA, Cunningham PB, Pickrel SG, et al. Multisystemic therapy effects on attempted suicide by youths presenting psychiatric emergencies. J Am Acad Child Adolesc Psychiatry. 2004;43(2):183–90.CrossRefPubMedGoogle Scholar
  64. 64.
    Remington G, Kapur S, Zipursky R. APA practice guideline for schizophrenia: risperidone equivalents. Am J Psychiatry. 1998;155(9):1301–2.CrossRefPubMedGoogle Scholar
  65. 65.
    Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156(4):544–9.PubMedGoogle Scholar
  66. 66.
    Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162(5):947–53.CrossRefPubMedGoogle Scholar
  67. 67.
    Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148(2):120–7.CrossRefPubMedGoogle Scholar
  68. 68.
    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.CrossRefPubMedGoogle Scholar
  69. 69.
    McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–10.CrossRefPubMedGoogle Scholar
  70. 70.
    Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003;64:14–7.CrossRefPubMedGoogle Scholar
  71. 71.
    Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090–5.CrossRefPubMedGoogle Scholar
  72. 72.
    Heilä H, Isometsä ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lönnqvist JK. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry. 1999;60(3):200–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Forrester T, Siskind D, Winckel K, Wheeler A, Hollingworth S. Increasing clozapine dispensing trends in Queensland, Australia 2004–2013. Pharmacopsychiatry. 2015;48:164–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Pankowski D, Kowalski J, Gawęda Ł. Skuteczność treningu metapoznawczego u osób chorujących na schizofrenię: narracyjny przegląd systematyczny badań opublikowanych w latach 2009–2015. Psychiatr Pol. 2016;50(4):787–803.CrossRefPubMedGoogle Scholar
  75. 75.
    Rapp CA, Goscha RJ. The principles of effective case management of mental health services. Psychiatr Rehabil J. 2004;27(4):319.CrossRefPubMedGoogle Scholar
  76. 76.
    Brown GW. Experiences of discharged chronic schizophrenic mental hospital patients in various types of living groups. Milbank Mem Fund Q. 1959;37:105–31.CrossRefPubMedGoogle Scholar
  77. 77.
    Goldstein MJ, Rodnick EH, Evans JR, May PR, Steinberg MR. Drug and family therapy in the aftercare of acute schizophrenics. Arch Gen Psychiatry. 1978;35(10):1169–77.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Tatiana Falcone
    • 1
    Email author
  • Migle Staniskyte
    • 2
  • Jane Timmons-Mitchell
    • 3
  1. 1.Epilepsy Center/ Psychiatry DepartmentNeurological Institute - Cleveland ClinicClevelandUSA
  2. 2.Neurologic Institute, Cleveland ClinicClevelandUSA
  3. 3.Begun Center for Violence Prevention Research and Education, Jack, Joseph, and Morton Mandel School of Applied Sciences, School of MedicineCase Western Reserve UniversityClevelandUSA

Personalised recommendations